



Contents lists available at ScienceDirect

## Bioorganic &amp; Medicinal Chemistry Letters

journal homepage: [www.elsevier.com/locate/bmcl](http://www.elsevier.com/locate/bmcl)

## A new phenylpropanoid and an alkylglycoside from *Piper retrofractum* leaves with their antioxidant and $\alpha$ -glucosidase inhibitory activity



Bui Thi Thuy Luyen<sup>a</sup>, Bui Huu Tai<sup>a,b</sup>, Nguyen Phuong Thao<sup>a,b</sup>, Seo Young Yang<sup>a</sup>, Nguyen Manh Cuong<sup>c</sup>, Young In Kwon<sup>d</sup>, Hae Dong Jang<sup>d</sup>, Young Ho Kim<sup>a,\*</sup>

<sup>a</sup> College of Pharmacy, Chungnam National University, Daejeon 305-764, Republic of Korea

<sup>b</sup> Institute of Marine Biochemistry (IMBC), Vietnam Academy of Science and Technology (VAST), 18 Hoang Quoc Viet, Cau Giay, Hanoi, Viet Nam

<sup>c</sup> Institute of Natural Products Chemistry, Vietnam Academy of Science and Technology (VAST), 18 Hoang Quoc Viet, Cau Giay, Hanoi, Viet Nam

<sup>d</sup> Department of Food and Nutrition, Hannam University, Daejeon 305-811, Republic of Korea

## ARTICLE INFO

## Article history:

Received 13 May 2014

Revised 8 July 2014

Accepted 19 July 2014

Available online 25 July 2014

## Keywords:

*Piper retrofractum*

Piperoside

Isoheptanol 2(S)-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 6)-O- $\beta$ -D-glucopyranoside

Antioxidant

 $\alpha$ -Glucosidase inhibitor

## ABSTRACT

Two new compounds, piperoside (**1**) and isoheptanol 2(S)-O- $\beta$ -D-xylopyranosyl (1 $\rightarrow$ 6)-O- $\beta$ -D-glucopyranoside (**11**), along with 10 known compounds 3,4-dihydroxyallylbenzene (**2**), 1,2-di-O- $\beta$ -D-glucopyranosyl-4-allylbenzene (**3**), tachioside (**4**), benzyl-O- $\beta$ -D-glucopyranoside (**5**), icaraside F<sub>2</sub> (**6**), dihydrovomifoliol-3'-O- $\beta$ -D-glucopyranoside (**7**), isopropyl O- $\beta$ -D-glucopyranoside (**8**), isopropyl primeveroside (**9**), *n*-butyl O- $\beta$ -D-glucopyranoside (**10**), isoheptanol 2(S)-O- $\beta$ -D-apiofuranosyl-(1 $\rightarrow$ 6)-O- $\beta$ -D-glucopyranoside (**12**), were isolated from the leaves of *Piper retrofractum*. Their structures were determined from 1D-NMR, 2D-NMR, and HR-ESI-MS spectral, a modified Mosher's method, and comparisons with previous reports. All of the isolated compounds showed modest  $\alpha$ -glucosidase inhibitory (4.60  $\pm$  1.74% to 11.97  $\pm$  3.30%) and antioxidant activities under the tested conditions.

© 2014 Elsevier Ltd. All rights reserved.


*Piper retrofractum* is widely distributed in tropical and subtropical regions of the world and is used medicinally in variety of preparations. In traditional medicine, *P. retrofractum* is often used as an anti-flatulent, expectorant, or antitussive agent. It exhibits antifungal, uterus-contractile, sedative-hypnotic, appetite-inducing, and counter-irritant properties and has been used to treat digestive and intestinal disorders.<sup>1</sup> The roots and fruits of *P. retrofractum* can act as stimulants and are used to treat asthma, bronchitis, hemorrhoids, fever, liver diseases, jaundice, edema, and abdominal pain.<sup>1,2</sup> Both the unripe and ripe fruits of *P. retrofractum* have been used as a spice in curries, preserves, and pickles. Phytochemical studies have characterized neurotrophic compounds,<sup>2</sup> as well as anti-obesity effects of alkaloids,<sup>3</sup> and the anti-leishmanial activity of amides and lignans found in *P. retrofractum*.<sup>4</sup> As part of an ongoing research program studying the bioactive components in *Piper* species, the methanolic extract of *P. retrofractum* was repeatedly fractionated through various column chromatographies (CC) containing silica gel, YMC C-18, and Diaion HP-20 resin, to isolate 12 compounds (see Fig. 1). Among them, two of which (**1** and **11**) are

new discoveries. In addition, the  $\alpha$ -glucosidase inhibitory and antioxidant activities of all of the isolated compounds were evaluated.

Compound **1**<sup>5</sup> was obtained as a pale yellow powder. The HR-ESI-MS spectrum showed a pseudo-molecular ion peak at  $m/z$  383.1316 [M+Na]<sup>+</sup> (Calcd for C<sub>16</sub>H<sub>24</sub>O<sub>9</sub>Na, 383.1318) which indicated a molecular formula of C<sub>16</sub>H<sub>24</sub>O<sub>9</sub>. In addition, an ESI-MS/MS experiment on ion 383.1316 showed fragments [M+Na-H<sub>2</sub>O]<sup>+</sup> at  $m/z$  365.12, [M+Na-C<sub>6</sub>H<sub>10</sub>O<sub>5</sub>]<sup>+</sup> at  $m/z$  221.07, and [M+Na-C<sub>6</sub>H<sub>10</sub>O<sub>5</sub>-H<sub>2</sub>O]<sup>+</sup> at  $m/z$  203.06. The <sup>1</sup>H NMR spectrum contained signals corresponding to three aromatic protons H-2' ( $\delta_H$  6.89, d,  $J$  = 1.8 Hz), H-5' ( $\delta_H$  7.06, d,  $J$  = 8.4 Hz) and H-6' ( $\delta_H$  6.76, dd,  $J$  = 1.8, 8.4 Hz), which indicate a 1,3,4-trisubstituted benzene ring system. Two double doublet methylene proton signals at  $\delta_H$  2.76 and 2.61 were assigned to benzylic methylene protons (H<sub>2</sub>-3). The signals from an anomeric proton H-1'' ( $\delta_H$  4.82, d,  $J$  = 7.8 Hz) and carbinol protons at  $\delta_H$  3.36–3.84 indicated the presence of a sugar unit in the structure of **1** (see Table 1). The <sup>13</sup>C NMR spectrum showed signals from 16 carbons atoms, which is in good agreement with its molecular formula of C<sub>16</sub>H<sub>24</sub>O<sub>9</sub>. Among these, a methoxy carbon ( $\delta_C$  56.7, 3'-OCH<sub>3</sub>), two methylene carbons [ $\delta_C$  66.5 (C-1) and 40.5 (C-3)], an oxygenated methine carbon ( $\delta_C$  74.9, C-2), and six aromatic carbons ( $\delta_C$  135.2,

\* Corresponding author. Tel.: +82 42 821 5933; fax: +82 42 823 6566.

E-mail address: [yhk@cnu.ac.kr](mailto:yhk@cnu.ac.kr) (Y.H. Kim).



**Figure 1.** The structures of isolated compounds **1–12** from the leaves of *Piper retrofractum*.

**Table 1**

The NMR spectroscopic data for compounds **1**, **11**, and **12** (in CD<sub>3</sub>OD)

Pos.	<b>1</b>		Pos.	<b>11</b>		Pos.	<b>12</b>	
	$\delta_C^a$	$\delta_H^b$ (mult., J in Hz)		$\delta_C^a$	$\delta_H^b$ (mult., J in Hz)		$\delta_C^a$	$\delta_H^b$ (mult., J in Hz)
1	66.5	3.46 <sup>*</sup> 3.43 <sup>*</sup>	1	22.1	1.20 (d, 6.6)	1	22.1	1.24 (d, 6.0)
2	74.9	3.17 (m)	2	77.8	3.78 (m)	2	77.9	3.78 <sup>*</sup>
3	40.5	2.76 (dd, 6.0; 13.8) 2.61 (dd, 7.8; 13.8)	3	37.7	1.61 (m) 1.43 <sup>*</sup> 1.43 <sup>*</sup>	3	37.7	1.63 (m) 1.44 <sup>*</sup>
1'	135.2	—	4	33.2	1.30 <sup>*</sup> 1.43 <sup>*</sup> 1.43 <sup>*</sup>	4	33.2	1.31 <sup>*</sup>
2'	115.0	6.89 (d, 1.8)	5	26.1	1.43 <sup>*</sup> 1.33 <sup>*</sup> 1.33 <sup>*</sup>	5	26.1	1.44 <sup>*</sup> 1.34 <sup>*</sup> 1.34 <sup>*</sup>
3'	150.5	—	6	23.7	1.33 <sup>*</sup>	6	23.7	1.34 <sup>*</sup>
4'	146.4	—	7	14.4	0.90 (t, 7.2)	7	14.4	0.92 (t, 7.8)
5'	118.1	7.06 (d, 8.4)	2-O-Glc			2-O-Glc		
6'	123.0	6.76 (dd, 1.8; 8.4)	1'	104.0	4.31 (d, 7.8)	1'	104.0	4.31 (d, 7.8)
4'-O-Glc			2'	75.2	3.13 <sup>*</sup>	2'	75.2	3.16 (dd, 7.8, 9.0)
1''	103.0	4.82 (d, 7.8)	3'	78.0	3.30 <sup>*</sup>	3'	78.0	3.35 (t, 9.0)
2''	74.4	3.77 <sup>*</sup>	4'	71.4	3.34 <sup>*</sup>	4'	71.7	3.27 (t, 9.0)
3''	78.1	3.36 <sup>*</sup>	5'	76.9	3.39 (m)	5'	76.7	3.40 (m)
4''	71.3	3.66 <sup>*</sup>	6'	69.7	4.05 (dd, 2.4, 11.7) 3.73 (dd, 6, 11.1)	6'	68.7	3.98 <sup>*</sup> 3.60 <sup>*</sup>
5''	77.8	3.44 <sup>*</sup>	6'-O-Xyl			6'-O-Api		
6''	62.5	3.84 <sup>*</sup> 3.67 <sup>*</sup>	1''	105.5	4.33 (d, 7.2)	1''	110.9	5.01 (d, 2.4)
3'-OMe	56.7	3.83 s	2''	74.8	3.18 <sup>*</sup>	2''	78.0	3.90 (d, 3.0)
			3''	77.7	3.30 <sup>*</sup>	3''	80.5	—
			4''	71.2	3.48 (m)	4''	74.9	3.97 <sup>*</sup> 3.77 <sup>*</sup>
			5''	66.9	3.18 <sup>*</sup> 3.85 (dd, 4.8, 11.7)	5''	65.6	3.59 <sup>*</sup>

Assignments were done by DEPT, HMQC, HMBC and COSY experiments.

<sup>a</sup> Measured at 150 MHz.

<sup>b</sup> Measured at 600 MHz.

<sup>\*</sup> Overlapped signals.

115.0, 150.5, 146.4, 118.1, and 123.0) were detected. Basically, the 1D NMR spectral patterns of **1** were similar to those of Guaiacylglycerol 4-O-β-D-glucopyranoside with the exception of the appearance of methylene group and the loss of one hydroxyl group at C-3.<sup>5</sup> Careful examination of HMBC spectra revealed a correlation between the methoxy proton ( $\delta_H$  3.83) and C-3' ( $\delta_C$  150.5). Furthermore, HMBC correlations H-2' ( $\delta_H$  6.89)/C-3' ( $\delta_C$  150.5), C-4'

( $\delta_C$  146.4), C-6' ( $\delta_C$  123.0), and C-3 ( $\delta_C$  40.5); H-5' ( $\delta_H$  7.06)/C-3' ( $\delta_C$  150.5), C-4' ( $\delta_C$  146.4), and C-1' ( $\delta_C$  135.2); and H-6' ( $\delta_H$  6.76)/C-2' ( $\delta_C$  115.0), C-4' ( $\delta_C$  146.4), C-3 ( $\delta_C$  40.5) were also observed (see Fig. 2). These indicated the structure of a 3-(4'-hydroxy-3'-methoxyphenyl)propan-1,2-diol. The position of the glucosyl linkage in **1** was supported by an HMBC correlation between the anomeric proton H-1'' ( $\delta_H$  4.82, d, J = 7.8 Hz) and C-4' ( $\delta_C$  146.4).




Figure 2. Important HMBC and COSY correlations for compounds **1** and **11**.

Thus, the glucose unit was bound to C-4'. Acid hydrolysis of **1** followed by TLC, GC analysis, and comparisons with authentic D-glucose, further confirmed the presence of D-glucose moiety in **1** (see Supporting information). Absolute configuration at C-2 of **1** was determined using a modified Mosher's method.<sup>7,8</sup> After acid hydrolysis, an aglycone **1a**<sup>9</sup> was individually reacted with (+) and (-) methoxytrifluoromethylphenylacetyl chlorides (MTPA-Cl) to obtain the (R)- and (S)-MTPA esters (**1b** and **1c**),<sup>10,11</sup> respectively (see Supporting information). The differences in the proton chemical shifts between the (S)-MTPA ester and the (R)-MTPA ester of **1a** (see Fig. 3) indicated an 'R' configuration at C-2.<sup>8</sup> Consequently, compound **1** was identified as 2(R)-3-(4'-O-β-D-glucopyranosyl-3'-methoxyphenyl)propane-1,2-diol, a new phenylpropanoid glycoside that we have named piperoside.

Compound **11**<sup>12</sup> was obtained as a colorless oil. The HR-ESI-MS spectrum showed a pseudo-molecular ion peak at  $m/z$  445.1848  $[M+Cl]^-$  (Calcd. for  $C_{18}H_{34}O_{10}Cl$ , 445.1846), which indicate a molecular formula of  $C_{18}H_{34}O_{10}$ . The <sup>1</sup>H NMR spectra of **11** contained signals corresponding to two methyl protons, which appeared as a doublet H-1 ( $\delta_H$  1.20, d,  $J = 6.6$  Hz) and a triplet H-7 ( $\delta_H$  0.90, t,  $J = 7.2$  Hz), an oxygenated methine proton H-2 ( $\delta_H$  3.78, m) and long chain methylene proton signals at  $\delta_H$  1.30 through 1.61. The signals of two anomeric protons H-1' ( $\delta_H$  4.31, d,  $J = 7.8$  Hz) and H-1'' ( $\delta_H$  4.33, d,  $J = 7.2$  Hz) indicated the presence of two sugar units. The <sup>13</sup>C NMR spectra displayed seven carbon signals corresponding to aglycone moiety, including two methyls ( $\delta_C$  14.4, 22.1), four methylenes ( $\delta_C$  23.7, 26.1, 33.2, 37.7) and an oxygenated methine carbon atom ( $\delta_C$  77.8), together with eleven carbon resonant signals of the sugar moiety ( $\delta_C$  66.9 through 105.5). The 1D-NMR spectra of **11** was similar to those of Shimaurosides B with the exception of the appearance of two more methylene groups.<sup>13</sup> Three individual correlations for the spin systems of H-1/H-2/H-3/H-4/H-5/H-6/H-7, H-1'/H-2'/H-3'/H-4'/H-5'/H-6', and H-1''/H-2''/H-3''/H-4''/H-5'' were observed in the COSY spectra of **11**, which supports the backbone proton assignments of the aglycone moiety and the two sugar units. HMBC correlations of xylose H-1'' ( $\delta_H$  4.33)/glucose C-6' ( $\delta_C$  69.7) and glucose H<sub>2</sub>-6'

( $\delta_H$  4.05, 3.73)/xylose C-1'' ( $\delta_C$  105.5) suggested the structure of a xylosyl(1→6)glucose disaccharide. The position of the sugar moiety in **11** was identified as C-2 based on HMBC correlations of the anomeric proton H-1' ( $\delta_H$  4.31)/C-2 ( $\delta_C$  77.8) and H-2 ( $\delta_H$  3.78)/C-1' ( $\delta_C$  104.0). In addition, acid hydrolysis experiments confirmed the presence of D-glucose and D-xylose in **11**. This conclusion was further supported by TLC, GC analysis, and comparisons with authentic D-glucose and D-xylose samples (see Supporting information). The stereochemistry at C-2 of **11** was determined by comparing the <sup>13</sup>C NMR data with those of previous reports. Agreement of the <sup>13</sup>C NMR chemical shift at C-2 ( $\delta_C$  77.8) of **11** with those of 2(S)- and 2(R)-pentanol-2-O-β-D-glucopyranoside [ $\delta_C$  78.2 for 2(S) and  $\delta_C$  75.1 for 2(R)] suggested an 'S' configuration at C-2.<sup>13</sup> Thus, compound **11** was identified as 2(S) isoheptanol 2-O-β-D-xylopyranosyl (1→6)-O-β-D-glucopyranoside.

Compound **12** was isolated as a colorless oil. In general, the <sup>1</sup>H and <sup>13</sup>C NMR data of **12** were similar to those of **11**. The differences between the spectra of **11** and **12** were with regard to the sugar moiety. The presence of an anomeric proton signal H-1'' ( $\delta_H$  5.01, d,  $J = 2.4$  Hz), an anomeric carbon signal C-1'' ( $\delta_C$  110.9), together with four other carbinol carbon signals C-2'' ( $\delta_C$  78.0), C-3'' ( $\delta_C$  80.5), C-4'' ( $\delta_C$  74.9), and C-5'' ( $\delta_C$  65.6) suggested the presence of an β-D-apiofuranose unit.<sup>14</sup> In addition, acid hydrolysis of **12** followed by TLC, GC analysis, and comparisons with authentic D-apiose, further confirmed the presence of D-apiose in **12** (see Supporting information). Thus, the xylose unit in **11** was replaced by an apiose moiety in **12**. The apiosyl(1→6)glucose disaccharide moiety was also confirmed by HMBC correlations H-1'' ( $\delta_H$  5.01)/C-6' ( $\delta_C$  68.7) and H<sub>2</sub>-6' ( $\delta_H$  3.60, 3.98)/C-1'' ( $\delta_C$  110.9). Therefore,




Figure 3.  $\Delta\delta$  values ( $\Delta\delta = \delta_S - \delta_R$  in ppm) obtained for MTPA esters **1b/1c**.

Table 2  
Rat intestinal  $\alpha$ -glucosidase inhibitory activities of compounds **1–12**

Compounds	% Enzyme inhibition
<b>1</b>	11.74 ± 2.58
<b>2</b>	9.08 ± 3.78
<b>3</b>	7.02 ± 5.49
<b>4</b>	4.60 ± 1.74
<b>5</b>	11.97 ± 3.30
<b>6</b>	7.93 ± 4.50
<b>7</b>	6.90 ± 4.39
<b>8</b>	7.31 ± 1.29
<b>9</b>	7.49 ± 4.50
<b>10</b>	9.75 ± 4.58
<b>11</b>	8.54 ± 2.94
<b>12</b>	8.62 ± 4.54
Acarbose*	50.96 ± 2.97

Percentage of enzyme inhibition at the concentration of 50  $\mu$ M.

\* Acarbose was used as positive controls. Data presented is the mean ± SD of samples run in triplicate.

**Table 3**  
Antioxidant activities of compounds **1–12**

Compounds	ORAC <sub>RCCO</sub> (TE, $\mu\text{M}$ )		Reduction power (Copper(I) ion, $\mu\text{M}$ )		Cu <sup>2+</sup> chelating activity (% vs control)
	1 $\mu\text{M}$	10 $\mu\text{M}$	1 $\mu\text{M}$	10 $\mu\text{M}$	10 $\mu\text{M}$
<b>1</b>	0.55 ± 0.18	2.88 ± 0.17	0.29 ± 0.19	0.96 ± 0.03	24.21 ± 1.18
<b>1a</b>	3.59 ± 0.80	28.20 ± 0.28	9.01 ± 0.06	43.82 ± 0.57	25.00 ± 0.90
<b>2</b>	2.55 ± 0.12	16.26 ± 0.50	1.55 ± 0.06	22.77 ± 0.28	20.48 ± 1.14
<b>3</b>	0.17 ± 0.20	1.71 ± 0.11	0.32 ± 0.11	0.65 ± 0.06	21.80 ± 0.35
<b>4</b>	0.21 ± 0.06	1.65 ± 0.14	0.21 ± 0.06	0.63 ± 0.31	21.42 ± 0.64
<b>5</b>	0.18 ± 0.17	1.83 ± 0.17	0.41 ± 0.12	0.69 ± 0.04	22.39 ± 0.55
<b>6</b>	0.15 ± 0.10	1.61 ± 0.22	0.46 ± 0.06	0.84 ± 0.11	19.30 ± 0.46
<b>7</b>	0.12 ± 0.23	0.92 ± 0.09	0.21 ± 0.06	0.34 ± 0.23	20.50 ± 0.31
<b>8</b>	0.22 ± 0.17	1.79 ± 0.15	0.29 ± 0.23	0.54 ± 0.15	20.97 ± 0.29
<b>9</b>	0.31 ± 0.22	2.13 ± 0.16	0.27 ± 0.09	0.63 ± 0.07	21.67 ± 1.43
<b>10</b>	0.62 ± 0.07	3.64 ± 0.05	0.18 ± 0.06	1.68 ± 0.09	18.04 ± 0.72
<b>11</b>	0.48 ± 0.08	2.26 ± 0.18	0.17 ± 0.08	0.59 ± 0.04	20.58 ± 0.37
<b>12</b>	1.04 ± 0.13	3.07 ± 0.12	0.34 ± 0.26	1.13 ± 0.13	19.63 ± 1.24

the structure of **12** was proposed to be isoheptanol 2-O- $\beta$ -D-apiofuranosyl (1 $\rightarrow$ 6)-O- $\beta$ -D-glucopyranoside, a new alkylglycoside isolated from *Hedychium yunnanense*.<sup>15</sup> Although the structure of compound **12** has been reported previously, the absolute configuration at C-2 of **12** has not been identified. Similar to compound **11**, the absolute configuration at C-2 was proposed to be 'S' based on a comparison of the chemical shift of C-2 ( $\delta_{\text{C}}$  77.9) with those of 2(S)- and 2(R)-pentanol- $\beta$ -D-glucopyranoside ['S'-form ( $\delta_{\text{C}}$  78.2), 'R'-form ( $\delta_{\text{C}}$  75.1)].<sup>13</sup> Compound **12** was therefore identified as 2(S) isoheptanol 2-O- $\beta$ -D-apiofuranosyl (1 $\rightarrow$ 6)-O- $\beta$ -D-glucopyranoside.

The remaining compounds were identified as 3,4-dihydroxyallylbenzene (**2**),<sup>16</sup> 1,2-di-O- $\beta$ -D-glucopyranosyl-4-allylbenzene (**3**),<sup>17</sup> tachioid (**4**),<sup>18</sup> benzyl-O- $\beta$ -D-glucopyranoside (**5**),<sup>19</sup> icaraside F<sub>2</sub> (**6**),<sup>20</sup> dihydrovomifoliol-O- $\beta$ -D-glucopyranoside (**7**),<sup>21</sup> isopropyl O- $\beta$ -D-glucopyranoside (**8**),<sup>22</sup> isopropyl primeveroside (**9**),<sup>23</sup> and n-butyl O- $\beta$ -D-glucopyranoside (**10**),<sup>24</sup> (see Fig. 1). Their structures were established based on spectroscopic and chemical evidence, which was in good agreement with those reported in literatures.

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by high blood glucose levels due to a deficiency in insulin secretion or/and insulin action. It has been estimated that diabetes affects approximately 4% of the worldwide population, which is expected to increase to 5.4% by 2025.<sup>25</sup> Intestinal  $\alpha$ -glucosidase is found in the epithelium of the small intestine and is a key enzyme in carbohydrate digestion and glucose absorption. The inhibition of intestinal  $\alpha$ -glucosidase can therefore delay the hydrolysis of carbohydrates and consequently reduce the incidence of postprandial hyperglycemia.<sup>26,27</sup> Therefore, administration of  $\alpha$ -glucosidase inhibitors is a plausible treatment for DM-type 2 and obesity.<sup>28,29</sup> Compounds **1–12** were evaluated for their  $\alpha$ -glucosidase inhibitory activity at a concentration of 50  $\mu\text{M}$ . Acarbose was used as the positive control with an inhibition of 50.96 ± 2.97% at a concentration of 50  $\mu\text{M}$ . The compounds isolated from *P. retrofractum* exhibited moderate  $\alpha$ -glucosidase inhibitory activity. The percentage of enzyme inhibition ranged from 4.60 ± 1.74% (**4**) to 11.97 ± 3.30% (**5**) at the same concentration (see Table 2). The antioxidant activities of compounds **1–12** were then measured using the oxygen radical absorbance capacity (ORAC), cupric ion reducing antioxidant capacity (CUPRAC), and metal chelating activity assays. Compound **2** showed a moderate peroxy radical scavenging activity and a reducing potential with ORAC and CUPRAC values of 16.26 ± 0.50, 22.77 ± 0.28 fold higher than those of the positive control (1.0  $\mu\text{M}$  of Trolox), respectively. The other isolated compounds exhibited relatively weak activities under the test conditions. At a concentration of 50  $\mu\text{M}$ , all of the compounds also exhibited weak metal chelating activities (see Table 3). According to previous study, aglycone **1a** was reported

in a mixture of both S-form and R-form. S-form was presented as major component. This mixture exhibited potentially antioxidant activities.<sup>30</sup> Thus, **1a** was also evaluated for antioxidant activities using the same method. The results showed that **1a** exhibited greater peroxy radical scavenging activity and a reducing potential activities than compound **1** with ORAC and CUPRAC values of 28.20 ± 0.28, 43.82 ± 0.57 at concentration of 10.0  $\mu\text{M}$ , respectively. While **1a** also showed weak Cu<sup>2+</sup> chelating activity at 50.0  $\mu\text{M}$  (see Table 3). These implied that the present of glucose may decrease the peroxy radical scavenging activity and a reducing potential activities but it do not effect for metal chelating activity on phenolic compound with a one hydroxy group on the aromatic ring.

## Acknowledgments

This work was supported by a grant from the Priority Research Center Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2009-0093815), Republic of Korea.

## Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bmcl.2014.07.057>.

## References and notes

- Lim, T. K. *Piper retrofractum, Edible Medicinal and Non-Medicinal Plants*; Springer: Netherlands, 2012. Vol. 4, p 351.
- Kubo, M.; Ishii, R.; Ishino, Y.; Harada, K.; Matsui, N.; Akagi, M.; Kato, E.; Hosoda, S.; Fukuyama, Y. *J. Nat. Prod.* **2013**, *76*, 769.
- Kim, K. J.; Lee, M. S.; Jo, K.; Hwang, J. K. *Biochem. Biophys. Res. Commun.* **2011**, *411*, 219.
- Bodiwala, H. S.; Singh, G.; Singh, R.; Dey, C. S.; Sharma, S. S.; Bhutani, K. K.; Singh, I. P. *J. Nat. Med.* **2007**, *61*, 418.
- Piperoside (1)*: Pale yellow powder;  $[\alpha]_{\text{D}}^{25} +186.6$  (c 0.32, MeOH); UV (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ): 274 (3.36) nm; IR (KBr)  $\nu_{\text{max}}$ : 3357, 2927, 1655, 1512, 1072  $\text{cm}^{-1}$ ; HR-ESI-MS  $m/z$  383.1316 [M+Na]<sup>+</sup> (Calcd for C<sub>16</sub>H<sub>24</sub>O<sub>9</sub>Na, 383.1318); <sup>1</sup>H and <sup>13</sup>C NMR data are given in the Table 1.
- Sugiyama, M.; Nagayama, E.; Kikuchi, M. *Phytochemistry* **1993**, *33*, 1215.
- Ohtani, I.; Kusumi, T.; Kashman, Y.; Kakisawa, H. *J. Am. Chem. Soc.* **1991**, *113*, 4092.
- Tai, B. H.; Huyen, V. T.; Huong, T. T.; Nguyen, X. N.; Choi, E. M.; Kim, J. A.; Long, P. Q.; Nguyen, M. C.; Kim, Y. H. *Chem. Pharm. Bull.* **2010**, *58*, 521.
- 3-(4-Hydroxy-3-methoxy-phenyl)propane-1,2-diol (1a)*: Colorless oil;  $[\alpha]_{\text{D}}^{25} +29.1^{\circ}$  (MeOH; c 0.15); <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz):  $\delta$  2.63 (1H, dd, J = 7.6; 13.8 Hz, H-3a), 2.76 (1H, dd, J = 5.6; 13.8 Hz, H-3b), 3.46 (1H, ddd, J = 4.0; 4.0; 12.0 Hz, H-1a), 3.53 (1H, ddd, J = 4.0; 4.0; 12.0 Hz, H-1b), 3.80 (1H, m, H-2), 3.87 (3H, s, 3'-OCH<sub>3</sub>), 6.69 (1H, dd, J = 2.0; 8.0 Hz, H-6'), 6.73 (1H, d, J = 8.0 Hz, H-5'), 6.86 (1H, d, J = 2.0 Hz, H-2'). <sup>13</sup>C NMR (CD<sub>3</sub>OD, 100 MHz):  $\delta$  40.5 (C-3), 56.4 (OCH<sub>3</sub>), 66.6 (C-1), 74.7 (C-2), 114.2 (C-2'), 116.0 (C-5'), 122.9 (C-6'), 131.6 (C-1'), 145.9 (C-4'), 148.8 (C-3').

10. (*R*)-MTPA ester (**1b**): Colorless oil; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 2.822 (1H, dd, *J* = 6.1; 13.8 Hz, H-3a), 2.913 (1H, dd, *J* = 7.2; 13.8 Hz, H-3b), 4.232 (1H, dd, *J* = 5.6; 12.3 Hz, H-1a), 4.676 (1H, dd, *J* = 2.8; 12.3 Hz, H-1b), 5.553 (1H, m, H-2), 6.623 (1H, dd, *J* = 1.7, 8.0 Hz, H-6'), 6.678 (1H, d, *J* = 1.7 Hz, H-2'), 6.849 (1H, d, *J* = 8.0 Hz, H-5'), 7.244–7.470 (H-MTPA).
11. (*S*)-MTPA ester (**1c**): Colorless oil; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 2.975 (2H, d, *J* = 7.2 Hz, H<sub>2</sub>-3), 4.207 (1H, dd, *J* = 4.0; 12.2 Hz, H-1a), 4.608 (1H, dd, *J* = 1.2; 12.2 Hz, H-1b), 5.516 (1H, m, H-2), 6.681 (1H, dd, *J* = 2.0, 8.1 Hz, H-6'), 6.770 (1H, br s, H-2'), 6.906 (1H, d, *J* = 8.1 Hz, H-5'), 7.210–7.469 (H-MTPA).
12. (*2S*)-Isoheptanol 2-*O*-β-*D*-xylopyranosyl (1→6)-*O*-β-*D*-glucopyranoside (**11**): Colorless oil; [α]<sub>D</sub><sup>21</sup> –74.4° (MeOH; *c* 0.04); IR (KBr) ν<sub>max</sub>: 3372, 2930, 1074 cm<sup>-1</sup>; HR-ESI-MS *m/z* 445.1848 [M+Cl]<sup>-</sup> (Calcd for C<sub>18</sub>H<sub>34</sub>O<sub>10</sub>Cl, 445.1846); <sup>1</sup>H and <sup>13</sup>C NMR data are given in the Table 1.
13. Kijima, H.; Otsuka, H.; Ide, T.; Ogimi, C.; Hirata, E.; Takushi, A.; Takeda, T. *Phytochemistry* **1996**, *42*, 723.
14. Guo, S.; Falk, E.; Kenne, L.; Ronnberg, B.; Sundquist, B. G. *Phytochemistry* **2000**, *53*, 861.
15. Zhao, Q.; Hao, X.; Zou, C.; Zhang, R.; Hu, J.; Yang, L. *Tianran Chanwu Yanjiu Yu Kaifa* **2008**, *20*, 761.
16. Fache, F.; Suzan, N.; Piva, O. *Tetrahedron* **2005**, *61*, 5261.
17. Ly, T. N.; Yamauchi, R.; Shimoyamada, M.; Kato, K. *J. Agric. Food Chem.* **2002**, *50*, 4919.
18. Zhong, X. N.; Otsuka, H.; Ide, T.; Hirata, E.; Takeda, Y. *Phytochemistry* **1999**, *52*, 923.
19. Yoneda, Y.; Krainz, K.; Liebner, F.; Potthast, A.; Rosenau, T.; Karakawa, M.; Nakatsubo, F. *Eur. J. Org. Chem.* **2008**, *2008*, 475.
20. Miyase, T.; Ueno, A.; Takizawa, N.; Kobayashi, H.; Oguchi, H. *Chem. Pharm. Bull.* **1988**, *36*, 2475.
21. Andersson, R.; Lundgren, L. N. *Phytochemistry* **1988**, *27*, 559.
22. Crich, D.; Cai, F. *Org. Lett.* **2007**, *9*, 1613.
23. Jaroszewski, J. W.; Rasmussen, A. B.; Rasmussen, H. B.; Olsen, C. E.; Jørgensen, L. B. *Phytochemistry* **1996**, *42*, 649.
24. Kurashima, K.; Fujii, M.; Ida, Y.; Akita, H. *J. Mol. Catal. B-Enzyme* **2003**, *26*, 87.
25. Yao, Y.; Chen, F.; Wang, M.; Wang, J.; Ren, G. *J. Agric. Food Chem.* **2008**, *56*, 8869.
26. Lebovitz, H. E. *Endocrinol. Metab. Clin. North Am.* **1997**, *26*, 539.
27. Derosa, G.; Maffioli, P. *Arch. Med. Sci.* **2012**, *8*, 899.
28. Scott, L. J.; Spencer, C. M. *Drugs* **2000**, *59*, 521.
29. Kordik, C. P.; Reitz, A. B. *J. Med. Chem.* **1999**, *42*, 181.
30. Kikuzaki, H.; Hara, S.; Kawai, Y.; Nakatani, N. *Phytochemistry* **1999**, *52*, 1307.